Nothing Special   »   [go: up one dir, main page]

WO2008138868A3 - In vitro diagnosis and/or prognosis of cancer by the analysis of gtpase protein expression - Google Patents

In vitro diagnosis and/or prognosis of cancer by the analysis of gtpase protein expression Download PDF

Info

Publication number
WO2008138868A3
WO2008138868A3 PCT/EP2008/055714 EP2008055714W WO2008138868A3 WO 2008138868 A3 WO2008138868 A3 WO 2008138868A3 EP 2008055714 W EP2008055714 W EP 2008055714W WO 2008138868 A3 WO2008138868 A3 WO 2008138868A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
rho
prognosis
expression profile
analysis
Prior art date
Application number
PCT/EP2008/055714
Other languages
French (fr)
Other versions
WO2008138868A2 (en
Inventor
Del Pulgar Ma Teresa Gomez
De Molina Ana Ramirez
Sanjuan Juan Carlos Lacal
Original Assignee
Traslational Cancer Drugs Phar
Consejo Superior Investigacion
Del Pulgar Ma Teresa Gomez
De Molina Ana Ramirez
Sanjuan Juan Carlos Lacal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Traslational Cancer Drugs Phar, Consejo Superior Investigacion, Del Pulgar Ma Teresa Gomez, De Molina Ana Ramirez, Sanjuan Juan Carlos Lacal filed Critical Traslational Cancer Drugs Phar
Publication of WO2008138868A2 publication Critical patent/WO2008138868A2/en
Publication of WO2008138868A3 publication Critical patent/WO2008138868A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to an in vitro method of diagnosis / prognosis of cancer, principally of breast cancer and / or lung cancer by the analysis in a single sample of either the expression profile of the Rnd2/Rho 7 protein, or simultaneously, the expression profile of the Rnd subfamily of proteins, comprised of the following proteins: Rndl / Rho 6, Rnd2 / Rho 7 and Rnd3 / RhoE / Rho8. Other GTPases of other subfamilies can be added to the expression profile of these proteins, such as: Rho, Rac, Cdc42, RhoBTB and Miro. The invention further comprises a test device which includes sequences of nucleic acids capable of hybridizing with sequences belonging to the genes of the different families of GTPases whose expression profile is to be measured. The use of these test devices permits, in addition to diagnosing the cancer, making a prognosis of development of the disease, as well as monitoring the treatments for its cure.
PCT/EP2008/055714 2007-05-09 2008-05-08 In vitro diagnosis and/or prognosis of cancer by the analysis of gtpase protein expression WO2008138868A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200701252 2007-05-09
ES200701252 2007-05-09

Publications (2)

Publication Number Publication Date
WO2008138868A2 WO2008138868A2 (en) 2008-11-20
WO2008138868A3 true WO2008138868A3 (en) 2009-01-08

Family

ID=39638728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/055714 WO2008138868A2 (en) 2007-05-09 2008-05-08 In vitro diagnosis and/or prognosis of cancer by the analysis of gtpase protein expression

Country Status (1)

Country Link
WO (1) WO2008138868A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2445627C1 (en) * 2010-09-02 2012-03-20 Учреждение Российской Академии Наук Институт Биологии Гена Ран Diagnosing technique for non-small-cell lung cancer and set for implementing thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050142580A1 (en) * 2003-09-03 2005-06-30 Tay Sun K. Methods and probes for diagnosing a gynaecological condition
WO2005115394A2 (en) * 2004-04-20 2005-12-08 New York University School Of Medicine Prenyl-electrostatic switch, and methods of use
WO2006016110A1 (en) * 2004-08-10 2006-02-16 University College Cardiff Consultants Limited Methods and kit for the prognosis of breast cancer
WO2006055833A2 (en) * 2004-11-19 2006-05-26 Children's Hospital Medical Center Gtpase inhibitors and use thereof for controlling platelet hyperactivity
WO2007005946A2 (en) * 2005-07-05 2007-01-11 Cytoskeleton Inc. Detection of rho proteins
EP1757692A1 (en) * 2004-04-21 2007-02-28 Daiichi Pharmaceutical Co., Ltd. GENE ENCODING GUANINE NUCLEOTIDE EXCHANGE FACTOR BINDING TO RhoA

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050142580A1 (en) * 2003-09-03 2005-06-30 Tay Sun K. Methods and probes for diagnosing a gynaecological condition
WO2005115394A2 (en) * 2004-04-20 2005-12-08 New York University School Of Medicine Prenyl-electrostatic switch, and methods of use
EP1757692A1 (en) * 2004-04-21 2007-02-28 Daiichi Pharmaceutical Co., Ltd. GENE ENCODING GUANINE NUCLEOTIDE EXCHANGE FACTOR BINDING TO RhoA
WO2006016110A1 (en) * 2004-08-10 2006-02-16 University College Cardiff Consultants Limited Methods and kit for the prognosis of breast cancer
WO2006055833A2 (en) * 2004-11-19 2006-05-26 Children's Hospital Medical Center Gtpase inhibitors and use thereof for controlling platelet hyperactivity
WO2007005946A2 (en) * 2005-07-05 2007-01-11 Cytoskeleton Inc. Detection of rho proteins

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BEKTIC J ET AL: "Identification of genes involved in estrogenic action in the human prostate using microarray analysis", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 83, no. 1, 1 January 2004 (2004-01-01), pages 34 - 44, XP004479145, ISSN: 0888-7543 *
CUIYAN ZHANG ET AL: "Overexpression of RhoE in Non-small Cell Lung Cancer (NSCLC) is associated with smoking and correlates with DNA copy number changes.", CANCER BIOLOGY & THERAPY MAR 2007, vol. 6, no. 3, March 2007 (2007-03-01), pages 335 - 342, XP002501355, ISSN: 1538-4047 *
FRITZ G ET AL: "Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 87, 1 January 2002 (2002-01-01), pages 635 - 644, XP002319076, ISSN: 0007-0920 *
HUANG HERVÉ ET AL: "Gene expression profiling and subgroup identification of oligodendrogliomas.", ONCOGENE 5 AUG 2004, vol. 23, no. 35, 5 August 2004 (2004-08-05), pages 6012 - 6022, XP002490600, ISSN: 0950-9232 *
ONGUSAHA ET AL: "RhoE Is a Pro-Survival p53 Target Gene that Inhibits ROCK I-Mediated Apoptosis in Response to Genotoxic Stress", CURRENT BIOLOGY, CURRENT SCIENCE, GB, vol. 16, no. 24, 18 December 2006 (2006-12-18), pages 2466 - 2472, XP005730864, ISSN: 0960-9822 *
VAYSSIERE B ET AL: "Interaction of the Grb7 adapter protein with Rnd1, a new member of the Rho family", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 467, no. 1, 4 February 2000 (2000-02-04), pages 91 - 96, XP004260929, ISSN: 0014-5793 *
VEGA F M ET AL: "Rho GTPases in cancer cell biology", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 582, no. 14, 18 June 2008 (2008-06-18), pages 2093 - 2101, XP022699971, ISSN: 0014-5793, [retrieved on 20080505] *
VEGA FRANCISCO M ET AL: "SnapShot: Rho family GTPases.", CELL 29 JUN 2007, vol. 129, no. 7, 29 June 2007 (2007-06-29), pages 1430, XP002501197, ISSN: 0092-8674 *
VILLALONGA PRIAM ET AL: "RhoE inhibits cell cycle progression and Ras-induced transformation.", MOLECULAR AND CELLULAR BIOLOGY SEP 2004, vol. 24, no. 18, September 2004 (2004-09-01), pages 7829 - 7840, XP002501196, ISSN: 0270-7306 *
WANG L ET AL: "A novel strategy for specifically down-regulating individual Rho GTPase activity in tumor cells", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 278, no. 45, 7 November 2003 (2003-11-07), pages 44617 - 44625, XP002312008, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2008138868A2 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
ATE436018T1 (en) IMPROVED IMMUNE TESTING PROCEDURES
WO2010053587A3 (en) Methods of monitoring conditions by sequence analysis
IL192866A (en) Detection of cancer by elevated levels of bcl-2
FI2398902T3 (en) Methods and compositions for diagnosis and treatment of cancer
EP2667194A3 (en) Ratio based biomarkers and methods of use thereof
JP2009501333A5 (en)
ES2530843T3 (en) MicroRNA based methods for the diagnosis of pancreatic cancer
ATE471512T1 (en) USE OF PROTEIN S100A 12 AS A MARKER FOR COLORECTAL CARCINOMA
EP2287618A3 (en) Method for diagnosing neuro-degenerative disease
WO2007080597A3 (en) Polynucleotide and polypeptide sequences and methods for diagnosis
RU2008101660A (en) METHOD FOR DIAGNOSTIC OF ALZHEIMER'S DISEASE
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
WO2007056523A3 (en) Methods for diagnosing and monitoring the progression of cancer
WO2009007958A3 (en) Compositions, methods and kits for the diagnosis of carriers of mutations in the brca1 and brca2 genes and early diagnosis of cancerous disorders associated with mutations in brca1 and brca2 genes
JP2009524829A5 (en)
WO2010136163A8 (en) Secernin-1 as a marker for cancer
MX2007008984A (en) Cancer markers and detection methods.
MX2012007009A (en) Method for diagnosing malignant tumor.
NZ592819A (en) Thyroid analyte detection and measurement
WO2008138868A3 (en) In vitro diagnosis and/or prognosis of cancer by the analysis of gtpase protein expression
JP2011519030A5 (en)
US20160327477A1 (en) Method for diagnosing lung diseases
CN104004851B (en) Candidiasis parting detecting reagent
DE602006018038D1 (en) MOLECULAR METHOD FOR DIAGNOSIS OF PROSTATE CANCER
DE602004001994D1 (en) USE OF THE PROTEIN MASP AS A MARKER FOR COLORECTAL CARCINOMAS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08750207

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08750207

Country of ref document: EP

Kind code of ref document: A2